BioCentury | Aug 5, 2020
Management Tracks

CureVac makes Haas’ CEO job permanent; plus Zhang now CEO of Legend and updates from Royalty, NBE, Black Diamond, VelosBio and more

COO Franz-Werner Haas will become CureVac AG ’s permanent CEO, the mRNA vaccines company’s third this year. He has filled the role on an interim basis since mid-March. CEO Ingmar Hoerr took a leave of...
BioCentury | Jul 30, 2020

With biggest biotech SPAC merger yet, Cerevel’s public path could augur more deals in same vein

Cerevel’s path to NASDAQ via a SPAC is likely to presage similar deals for other life sciences companies. Biotechs and investors have increasingly made use this year of special purpose acquisition companies, which are blank-check...
BioCentury | Jul 25, 2020
Product Development

Real-world data’s power to increase racial diversity in clinical research

Real-world data has come into focus as one of the most important resources for accelerating drug development and defining the natural history of the disease during the pandemic, but it also represents one of the...
BioCentury | Jul 25, 2020

Preclinical IPOs attracting big money, but yet to see exponential growth of clinical peers

An analysis of preclinical IPO performance since the window opened eight years ago shows the companies have done about as well as their clinical peers. What’s missing are standout examples of explosive growth, though those...
BioCentury | Jul 22, 2020
Product Development

Novavax on track to deliver Operation Warp Speed promise

Novavax is on track to deliver 100 million doses of COVID-19 vaccine NVX-CoV2373 to the U.S. by year-end, according to remarks made Tuesday by President of R&D Gregory Glenn. Novavax Inc. (NASDAQ:NVAX) committed to the...
BioCentury | Jul 18, 2020
Management Tracks

Genzyme vet Modur joins Zikani; plus Scholar Rock, Poseida, Ribon, Kiadis and more

Zikani Therapeutics Inc. hired Vijay Modur as chief scientific and medical officer. He was global project head in rare disease clinical development at the Genzyme unit of Sanofi (Euronext:SAN; NASDAQ:SNY). Zikani is developing ribosome modulating...
BioCentury | Jul 17, 2020

Survey: biotechs adapting to COVID-19 era, optimistic about 2021

As biotechs look ahead to 2021, they may not see an end to the pandemic but they are optimistic that virtually all business activities will rebound to some extent, reflecting a net positive outlook. A...
BioCentury | Jul 16, 2020
Management Tracks

NextCure CMO Heller to resign; plus Vertex, Turning Point, Scholar Rock, C4, Vor and more

NextCure Inc. (NASDAQ:NXTC) said CMO Kevin Heller has resigned, effective Aug. 4, to pursue a new opportunity; the immunotherapy company is searching for a successor. NextCure also said Monday that, based on response data, it...
BioCentury | Jul 15, 2020
Product Development

INmune therapy shows promise in Alzheimer’s, but cognitive test still to come

After reporting its TNF inhibitor reduced brain inflammation in Alzheimer’s disease patients, INmune will need to show that reducing inflammation translates into a cognitive benefit in a Phase II trial planned for next year. The...
BioCentury | Jul 14, 2020

Three biotechs step up to the IPO plate following Nkarta’s debut

Berkeley Lights, ALX and Pandion are next in line for NASDAQ debuts as massive inflows into the sector continue to prompt upsized offerings, and double- to triple-digit aftermarket moves. If each biotech priced at the...
Items per page:
1 - 10 of 3341